Suchergebnisse - "Boeree, M."

Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis von Stott, K E, Pertinez, H, Sturkenboom, M G G, Boeree, M J, Aarnoutse, R, Ramachandran, G, Requena-Méndez, A, Peloquin, C, Koegelenberg, C F N, Alffenaar, J W C, Ruslami, R, Tostmann, A, Swaminathan, S, McIlleron, H, Davies, G

“… The objectives of this study were to explore inter-study heterogeneity in the pharmacokinetics (PK) of orally administered rifampicin, to derive summary …”
Weitere Angaben

Clinical relevance of non-tuberculous mycobacteria isolated in the Nijmegen-Arnhem region, The Netherlands von van Ingen, J, Bendien, S A, de Lange, W C M, Hoefsloot, W, Dekhuijzen, P N R, Boeree, M J, van Soolingen, D

“… Background:The frequency of clinical isolation of non-tuberculous mycobacteria (NTM) in the Netherlands is increasing, but its clinical relevance is often …”
Volltext

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis von Aarnoutse, R E, Kibiki, G S, Reither, K, Semvua, H H, Haraka, F, Mtabho, C M, Mpagama, S G, van den Boogaard, J, Sumari-de Boer, I M, Magis-Escurra, C, Wattenberg, M, Logger, J G M, Te Brake, L H M, Hoelscher, M, Gillespie, S H, Colbers, A, Phillips, P P J, Plemper van Balen, G, Boeree, M J

“… In a multiple-dose-ranging trial, we previously evaluated higher doses of rifampin in patients for 2 weeks. The objectives of the current study were to …”
Weitere Angaben

If you want to go far, go together: standardisation and data sharing in TB drug development von Schildkraut, J A, Sloan, D, Boeree, M J

Weitere Angaben

Low-level rifampicin-resistant Mycobacterium tuberculosis strains raise a new therapeutic challenge von van Ingen, J, Aarnoutse, R, de Vries, G, Boeree, M J, van Soolingen, D

“… In an outbreak of multidrug-resistant tuberculosis, the outbreak strain had an Asp516Tyr rpoB gene mutation. Phenotypically, low-level rifampicin (RMP) …”
Weitere Angaben

UNITE4TB: a new consortium for clinical drug and regimen development for TB von Boeree, M J, Lange, C, Thwaites, G, Paton, N, de Vrueh, R, Barros, D, Hoelscher, M

Weitere Angaben

A phase IIb, open-label, randomized controlled dose ranging multi-centre trial to evaluate the safety, tolerability, pharmacokinetics and exposure-response relationship of different doses of delpazolid in combination with bedaquiline delamanid moxifloxacin in adult subjects with newly diagnosed, uncomplicated, smear-positive, drug-sensitive pulmonary tuberculosis von Dierig, A, Hoelscher, M, Schultz, S, Hoffmann, L, Jarchow-MacDonald, A, Svensson, EM, Te Brake, L, Aarnoutse, R, Boeree, M, McHugh, TD, Wildner, LM, Gong, X, Phillips, PPJ, Minja, LT, Ntinginya, N, Mpagama, S, Liyoyo, A, Wallis, RS, Sebe, M, Mhimbira, FA, Mbeya, B, Rassool, M, Geiter, L, Cho, YL, Heinrich, N

“… Background Linezolid is an effective, but toxic anti-tuberculosis drug that is currently recommended for the treatment of drug-resistant tuberculosis. Improved …”
Volltext

Diagnosis, treatment and transmission of rifampicin-resistant TB in the Netherlands, 2010-2019 von de Vries, G, Akkerman, O, Boeree, M, van Hest, R, Kamst, M, de Lange, W, Magis-Escurra, C, Meijer, W, van Soolingen, D

“… New tools for diagnosis and treatment of rifampicin-resistant (RR-) and multidrug-resistant (MDR-) TB have become available in the last decade, including …”
Weitere Angaben

Proposal to elevate Mycobacterium avium complex ITS sequevar MAC-Q to Mycobacterium vulneris sp. nov von van Ingen, J, Boeree, M J, Kösters, K, Wieland, A, Tortoli, E, Dekhuijzen, P N R, van Soolingen, D

“… The Mycobacterium avium complex (MAC) consists of four recognized species, Mycobacterium avium, Mycobacterium colombiense, Mycobacterium intracellulare and …”
Weitere Angaben

The changing pattern of clinical Mycobacterium avium isolation in the Netherlands von van Ingen, J, Hoefsloot, W, Dekhuijzen, P N R, Boeree, M J, van Soolingen, D

“… National Mycobacteria Reference Laboratory, The Netherlands. To assess the role of factors other than laboratory improvements in the increasing frequency of …”
Weitere Angaben

Environmental sources of rapid growing nontuberculous mycobacteria causing disease in humans von van Ingen, J., Boeree, M.J., Dekhuijzen, P.N. R., van Soolingen, D.

“… Nontuberculous mycobacteria are environmental, opportunistic pathogens whose role in human disease is increasingly recognized, especially regarding the rapid …”
Volltext

Clinical relevance of Mycobacterium malmoense isolation in The Netherlands von Hoefsloot, W, van Ingen, J, de Lange, W C M, Dekhuijzen, P N R, Boeree, M J, van Soolingen, D

“… Uncertainty exists about the clinical relevance of Mycobacterium malmoense isolation, especially in pulmonary samples. We therefore determined clinical …”
Weitere Angaben

Highly successful treatment outcome of multidrug-resistant tuberculosis in the Netherlands, 2000-2009 von van Altena, R, de Vries, G, Haar, C H, de Lange, W C M, Magis-Escurra, C, van den Hof, S, van Soolingen, D, Boeree, M J, van der Werf, T S

“… Resistance to the two key anti-tuberculosis drugs isoniazid and rifampicin is a characteristic of multidrug-resistant tuberculosis (MDR-TB). MDR-TB is a …”
Weitere Angaben

Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteers von la Porte, C J L, Colbers, E P H, Bertz, R, Voncken, D S, Wikstrom, K, Boeree, M J, Koopmans, P P, Hekster, Y A, Burger, D M

“… Coadministration of lopinavir-ritonavir, an antiretroviral protease inhibitor, at the standard dose (400/100 mg twice a day [BID]) with the antituberculous …”
Weitere Angaben

Evaluation of a national multidisciplinary meeting for non-tuberculous mycobacterial disease von Lemson, A., Koster, T.A., Carpaij, N., Magis-Escurra, C., Boeree, M., Stemkens, R., Aarnoutse, R.E., van Laarhoven, A., van Crevel, R., van Ingen, J., Hoefsloot, W.

Volltext

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin von Magis-Escurra, C., Later-Nijland, H.M.J., Alffenaar, J.W.C., Broeders, J., Burger, D.M., van Crevel, R., Boeree, M.J., Donders, A.R.T., van Altena, R., van der Werf, T.S., Aarnoutse, R.E.

“… Therapeutic drug monitoring (TDM) of tuberculosis (TB) drugs currently focuses on peak plasma concentrations, yet total exposure [area under the 24-h …”
Volltext

Mycobacterium genavense in the Netherlands: an opportunistic pathogen in HIV and non-HIV immunocompromised patients. An observational study in 14 cases von Hoefsloot, W., van Ingen, J., Peters, E.J.G., Magis-Escurra, C., Dekhuijzen, P.N.R., Boeree, M.J., van Soolingen, D.

“… Mycobacterium genavense is an opportunistic non-tuberculous mycobacterium previously mostly associated with HIV-infected patients with CD4 counts below 100/µL …”
Volltext

Clinical relevance of Mycobacterium simiae in pulmonary samples von van Ingen, J, Boeree, M J, Dekhuijzen, P N R, van Soolingen, D

“… The aim of the present study was to determine the clinical relevance of Mycobacterium simiae isolation from clinical samples. The medical files of patients in …”
Weitere Angaben

Ebola, fragile health systems and tuberculosis care: a call for pre-emptive action and operational research von Zachariah, R, Ortuno, N, Hermans, V, Desalegn, W, Rust, S, Reid, A J, Boeree, M J, Harries, A D

“… The Ebola outbreak that started in late 2013 is by far the largest and most sustained in history. It occurred in a part of the world where pre-existing health …”
Weitere Angaben

Breakpoints and drug exposure are inevitably closely linked von Alffenaar, J W C, Akkerman, O W, Bolhuis, M S, Boeree, M J, de Lange, W C M, van der Werf, T S

Weitere Angaben